Everolimus

This classification denotes a mtor inhibitor and immunosuppressant with the molecular formula C53H83NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9HW64Q8G6G, chemically known as rapamycin, 42-o-(2-hydroxyethyl)- but more generally known as everolimus, which bears US NIH Compound Identifier 6442177. European Medicines Agency schedules Everolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02065MIG. The term EVEROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules everolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule everolimus under HS 29349990 and SITC 51579. As of Q4 2014, EVEROLIMUS remains US FDA's Preferred Term for this commodity. Everolimus bears US NLM identifiers UMLS ID C0541315 and NCI Concept Code C48387. SMILES: O(C1C(OC)CC(CC1)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)CCO.